IDT Biologika and Exothera Partner on Viral Vaccines Manufacturing

IDT Biologika, a contract development and manufacturing organization (CDMO) specializing in vaccines, gene and immune therapy, and oncolytic viruses, and Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, announced on March 1, 2022 that they have formed a collaboration to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study they will conduct will focus on Modified Vaccinia Ankara (MVA) virus as the first target for IDT’s vector technologies.

Exothera has done a successful transfer of IDT Biologika’s upstream process from small-scale to large-scale in the NevoLine upstream platform (Univercells Technologies). The NevoLine platform incorporates the scale-X structured fixed-bed bioreactor system. This system offers a range of scalable options to smoothly scale viral production from R&D to commercialization, according to a company press release.

“At Exothera we’re excited to be working collaboratively with IDT Biologika to leverage Univercells Technologies’ novel manufacturing platforms to design a high-quality, and cost-effective commercial process for the viral vector-based industry,” said Romain de Rauville, vice-president, Business Development, Exothera in the press release.

“Viral vaccines have been receiving special attention since the launch of COVID vaccines; however, they had been important for many vaccine programs in the past already. IDT Biologika has a strong track record in development and manufacturing of vaccine candidates; this is why our researchers are continuously looking for options to further optimize our processes in terms of quality and efficiency. The Univercells Technologies equipment is one further milestone on this path,” said Simone Kardinahl, senior vice-president, Development, IDT Biologika, in the press release.

Source: IDT Biologika